• Home
  • Pharmaceuticals and Healthcare
Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Global Outlook and Forecast 2021-2027

Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Global Outlook and Forecast 2021-2027

Report Code: KNJ777325 | No. of Pages: 94 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: Jun-2021 
This report contains market size and forecasts of Amyotrophic Lateral Sclerosis (ALS) Treatment in Global, including the following market information:
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Amyotrophic Lateral Sclerosis (ALS) Treatment market was valued at 303.2 million in 2020 and is projected to reach US$ 391.6 million by 2027, at a CAGR of 6.6% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Segment Percentages, By Type, 2020 (%)
    Riluzole
    Edaravone (Radicava)
    Other

China Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Segment Percentages, By Application, 2020 (%)
    Hospital
    Drugs Store
    Other

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Segment Percentages, By Region and Country, 2020 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Total Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Amyotrophic Lateral Sclerosis (ALS) Treatment Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
    Mitsubishi Tanabe Pharma
    Sanofi
    Mylan Pharma
    Apotex
    Glemark Generics
    Covis Pharma
    Sun Pharma
    Lunan Pharma
1 Introduction to Research & Analysis Reports
    1.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Overall Market Size
    2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size: 2021 VS 2027
    2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Prospects & Forecasts: 2016-2027
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players in Global Market
    3.2 Top Global Amyotrophic Lateral Sclerosis (ALS) Treatment Companies Ranked by Revenue
    3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Companies
    3.4 Top 3 and Top 5 Amyotrophic Lateral Sclerosis (ALS) Treatment Companies in Global Market, by Revenue in 2020
    3.5 Global Companies Amyotrophic Lateral Sclerosis (ALS) Treatment Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players in Global Market
        3.6.1 List of Global Tier 1 Amyotrophic Lateral Sclerosis (ALS) Treatment Companies
        3.6.2 List of Global Tier 2 and Tier 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Markets, 2021 & 2027
        4.1.2 Riluzole
        4.1.3 Edaravone (Radicava)
        4.1.4 Other
    4.2 By Type - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue & Forecasts
        4.2.1 By Type - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2021
        4.2.2 By Type - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2022-2027
        4.2.3 By Type - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share, 2016-2027
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2021 & 2027
        5.1.2 Hospital
        5.1.3 Drugs Store
        5.1.4 Other
    5.2 By Application - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue & Forecasts
        5.2.1 By Application - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2021
        5.2.2 By Application - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2022-2027
        5.2.3 By Application - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share, 2016-2027
6 Sights by Region
    6.1 By Region - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2021 & 2027
    6.2 By Region - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue & Forecasts
        6.2.1 By Region - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2021
        6.2.2 By Region - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2022-2027
        6.2.3 By Region - Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share, 2016-2027
    6.3 North America
        6.3.1 By Country - North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2027
        6.3.2 US Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.3.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.3.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
    6.4 Europe
        6.4.1 By Country - Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2027
        6.4.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.4.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.4.4 U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.4.5 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.4.6 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.4.7 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.4.8 Benelux Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
    6.5 Asia
        6.5.1 By Region - Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2027
        6.5.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.5.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.5.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.5.5 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.5.6 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
    6.6 South America
        6.6.1 By Country - South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2027
        6.6.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.6.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, 2016-2027
        6.7.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.7.3 Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.7.4 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
        6.7.5 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, 2016-2027
7 Players Profiles
    7.1 Mitsubishi Tanabe Pharma
        7.1.1 Mitsubishi Tanabe Pharma Corporate Summary
        7.1.2 Mitsubishi Tanabe Pharma Business Overview
        7.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.1.5 Mitsubishi Tanabe Pharma Key News
    7.2 Sanofi
        7.2.1 Sanofi Corporate Summary
        7.2.2 Sanofi Business Overview
        7.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.2.5 Sanofi Key News
    7.3 Mylan Pharma
        7.3.1 Mylan Pharma Corporate Summary
        7.3.2 Mylan Pharma Business Overview
        7.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.3.5 Mylan Pharma Key News
    7.4 Apotex
        7.4.1 Apotex Corporate Summary
        7.4.2 Apotex Business Overview
        7.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.4.5 Apotex Key News
    7.5 Glemark Generics
        7.5.1 Glemark Generics Corporate Summary
        7.5.2 Glemark Generics Business Overview
        7.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.5.5 Glemark Generics Key News
    7.6 Covis Pharma
        7.6.1 Covis Pharma Corporate Summary
        7.6.2 Covis Pharma Business Overview
        7.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.6.5 Covis Pharma Key News
    7.7 Sun Pharma
        7.7.1 Sun Pharma Corporate Summary
        7.7.2 Sun Pharma Business Overview
        7.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.4.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.7.5 Sun Pharma Key News
    7.8 Lunan Pharma
        7.8.1 Lunan Pharma Corporate Summary
        7.8.2 Lunan Pharma Business Overview
        7.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Major Product Offerings
        7.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in Global (2016-2021)
        7.8.5 Lunan Pharma Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com